Farche M, Fachinetti N, da Silva L, Matos L, Appenzeller S, Cendes F
Neuroradiol J. 2022; 35(5):619-626.
PMID: 35446177
PMC: 9513916.
DOI: 10.1177/19714009221083145.
Semmineh N, Bell L, Stokes A, Hu L, Boxerman J, Quarles C
AJNR Am J Neuroradiol. 2018; 39(11):1981-1988.
PMID: 30309842
PMC: 6239921.
DOI: 10.3174/ajnr.A5827.
Semmineh N, Stokes A, Bell L, Boxerman J, Quarles C
Tomography. 2017; 3(1):41-49.
PMID: 28584878
PMC: 5454781.
DOI: 10.18383/j.tom.2016.00286.
Fink J, Muzi M, Peck M, Krohn K
J Nucl Med. 2015; 56(10):1554-61.
PMID: 26294301
PMC: 4592410.
DOI: 10.2967/jnumed.113.131516.
She D, Xing Z, Zeng Z, Shang X, Cao D
Neuroradiology. 2014; 57(3):275-81.
PMID: 25487356
DOI: 10.1007/s00234-014-1475-3.
Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Xing Z, You R, Li J, Liu Y, Cao D
Clin Neuroradiol. 2013; 24(4):329-36.
PMID: 23994941
DOI: 10.1007/s00062-013-0255-5.
True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song Y, Choi S, Park C, Yi K, Lee W, Yun T
Korean J Radiol. 2013; 14(4):662-72.
PMID: 23901325
PMC: 3725362.
DOI: 10.3348/kjr.2013.14.4.662.
MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.
Blasel S, Jurcoane A, Bahr O, Weise L, Harter P, Hattingen E
J Neurooncol. 2013; 114(1):127-34.
PMID: 23695516
DOI: 10.1007/s11060-013-1161-z.
Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.
Essock-Burns E, Phillips J, Molinaro A, Lupo J, Cha S, Chang S
J Magn Reson Imaging. 2013; 38(2):388-400.
PMID: 23281184
PMC: 3711964.
DOI: 10.1002/jmri.23982.
Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S, Muldoon L, Varallyay C, Li X, Kraemer D, Fu R
Radiology. 2012; 266(3):842-52.
PMID: 23204544
PMC: 3579176.
DOI: 10.1148/radiol.12111472.
Comparison of dual-echo DSC-MRI- and DCE-MRI-derived contrast agent kinetic parameters.
Quarles C, Gore J, Xu L, Yankeelov T
Magn Reson Imaging. 2012; 30(7):944-53.
PMID: 22617148
PMC: 3569857.
DOI: 10.1016/j.mri.2012.03.008.
Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
Gahramanov S, Muldoon L, Li X, Neuwelt E
Radiology. 2011; 261(3):796-804.
PMID: 21940504
PMC: 3219915.
DOI: 10.1148/radiol.11103503.
Arterial spin labeling and dynamic susceptibility contrast CBF MRI in postischemic hyperperfusion, hypercapnia, and after mannitol injection.
Tanaka Y, Nagaoka T, Nair G, Ohno K, Duong T
J Cereb Blood Flow Metab. 2010; 31(6):1403-11.
PMID: 21179070
PMC: 3130313.
DOI: 10.1038/jcbfm.2010.228.
Comment to: Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma: pitfalls in perfusion MRI in brain tumors : Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC,....
Radbruch A, Bendszus M, Wick W, Heiland S
Clin Neuroradiol. 2010; 20(3):183-4.
PMID: 20734016
DOI: 10.1007/s00062-010-0024-7.
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Barajas Jr R, Chang J, Segal M, Parsa A, McDermott M, Berger M
Radiology. 2009; 253(2):486-96.
PMID: 19789240
PMC: 2770116.
DOI: 10.1148/radiol.2532090007.
A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation.
Quarles C, Gochberg D, Gore J, Yankeelov T
Phys Med Biol. 2009; 54(19):5749-66.
PMID: 19729712
PMC: 2767268.
DOI: 10.1088/0031-9155/54/19/006.
Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.
Paulson E, Schmainda K
Radiology. 2008; 249(2):601-13.
PMID: 18780827
PMC: 2657863.
DOI: 10.1148/radiol.2492071659.
Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: a magnetic resonance imaging study.
Tanaka Y, Ishii H, Hiraoka M, Miyasaka N, Kuroiwa T, Hajjar K
Brain Res. 2007; 1165:135-43.
PMID: 17651708
PMC: 2900767.
DOI: 10.1016/j.brainres.2007.06.039.
Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Cha S, Lupo J, Chen M, Lamborn K, McDermott M, Berger M
AJNR Am J Neuroradiol. 2007; 28(6):1078-84.
PMID: 17569962
PMC: 8134129.
DOI: 10.3174/ajnr.A0484.
Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.
Lupo J, Cha S, Chang S, Nelson S
AJNR Am J Neuroradiol. 2005; 26(6):1446-54.
PMID: 15956514
PMC: 8149056.